相关临床试验
5
5 进行中
药物批准
60
批准总数
监管机构
1
监管机构数
成立时间
N/A
进行中（未招募）
5
100.0%
- The UK's MHRA approved inavolisib (Itovebi) on November 26, 2025, for adults with HR-positive, HER2-negative breast cancer that has returned during or after hormone therapy and spread to other body parts. - The oral film-coated tablet provides a new targeted treatment option for patients whose cancer shows specific genetic changes and helps delay disease progression. - Common side effects include high blood sugar, mouth inflammation, diarrhea, tiredness, and anemia, with the medicine subject to additional safety monitoring.
- The NHS has approved glofitamab (Columvi) for around 300 patients annually with relapsed or refractory diffuse large B-cell lymphoma after just one previous treatment, expanding access from the previous requirement of two failed treatments. - Clinical trial data shows nearly 60% of patients achieved complete remission with glofitamab plus chemotherapy, with 54% survival at two years compared to 34% with standard treatment. - The drug will be available immediately through the NHS Cancer Drugs Fund, representing a significant advancement for patients with this aggressive form of non-Hodgkin lymphoma that affects approximately 5,500 people annually in England.
- The NHS has approved glofitamab (Columvi®) for diffuse large B-cell lymphoma (DLBCL) patients who have undergone two or more ineffective treatments. - Clinical trials have demonstrated glofitamab's potential to cure DLBCL, offering a new treatment option for approximately 5,500 people diagnosed annually in England. - Glofitamab, administered intravenously, activates the patient's own T-cells to target and eliminate lymphoma cells, reducing the need for chemotherapy and its associated side effects. - The Cancer Drugs Fund (CDF) will expedite access to glofitamab, making it available at more cancer treatment centers across the country, including for patients who may not have responded to or are not eligible for CAR T-cell therapy.
